A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (NCT04486352)
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- City of Hope Comprehensive Cancer Center — Duarte, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Medstar Georgetown Cancer Institute — Washington D.C., District of Columbia
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
- University of Chicago — Chicago, Illinois
- University of Kansas Cancer Center — Westwood, Kansas
- Maine Medical Center — Scarborough, Maine
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Minnesota — Minneapolis, Minnesota
- Washington University School of Medicine Siteman Cancer Center — St Louis, Missouri
- Nebraska Methodist Hospital — Omaha, Nebraska
- Englewood Health — Englewood, New Jersey
- Atlantic Health Systems/Morristown Medical Center — Morristown, New Jersey
- Roswell Park — Buffalo, New York
- Weill Cornell Medicine — New York, New York
- Duke University Cancer Center — Durham, North Carolina
- University of Oklahoma Health Stephenson Cancer Center — Oklahoma City, Oklahoma
- Providence Portland Cancer Institute — Portland, Oregon
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Lifespan - Rhode Island Hospital — Providence, Rhode Island
- Baptist Memorial Hospital — Memphis, Tennessee
📞 Contact the Study Coordinator
Phone: (617) 732-8727
Email: ClinicalTrials.Queries@alliancefoundationtrials.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Cancer
- Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation — Lexington, Kentucky
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Mobile, Alabama
- Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer — Houston, Texas
- A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer — Little Rock, Arkansas
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line — Garran,
- Activity and Cancer Survivorship Exercise Pilot — Iowa City, Iowa
Explore by condition: All Endometrial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.